Evidence reviews - September 2025
The following documents contain the evidence that was used to develop the 2025 recommendations:
- Medicines for heart failure with reduced ejection fraction
- Medicines for heart failure with mildly reduced ejection fraction
- IV iron therapy for heart failure
- Mineralocorticoid receptor antagonist therapy for heart failure with preserved ejection fraction
Other supporting evidence
The following documents contain the evidence that was used to develop the 2018 recommendations:
This page was last updated: